Drugs / IM-1617
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07578571 | May 2026 → Jan 2029 expected | breast cancer, colorectal cancer, esophageal cancer, gastric cancer +1 | Immunome, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-11 | Immunome, Inc. | Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors immunome.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IM-1617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07578571 ↗ |
| Modality | Other / unclassified | “IM-1617 is an antibody-drug conjugate” NCT07578571 ↗ |
| Route | Intravenous | “IM-1617 given into the vein (IV; intravenously)” NCT07578571 ↗ |